Company / SG&A Expense
QuidelOrtho SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$746.3M
FY2025
5-year range
$180.7M / $766.8M
FY2021-FY2025
Trend
-2.7%
vs FY2024
Sector context
#51 of 152
Health Care
What the data says
At $746M, QuidelOrtho's sg&a expense ranks #102 of 152 in the Health Care sector. Improved from $763M to $746M over the past 2 years.
Based on SEC 10-K filings.
$746M in FY2025 with a 5-year CAGR of +32.8%.
Improved from $763M to $746M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +6.3%
- 5-Year CAGR
- +32.8%
- 10-Year CAGR
- -
Sector benchmark
#102 of 152 in Health CareTop 66% of 152This company $746.3M Sector average $182.7B
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +32.8%, indicating consistent growth.
- In FY2025, sg&a expense decreased 2.7% year-over-year.
- Ranks #51 out of 152 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $746.3M | -2.7% |
| FY2024 | $766.8M | +0.5% |
| FY2023 | $763.2M | +22.9% |
| FY2022 | $621.0M | +243.7% |
| FY2020 | $180.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026